Search clinical trials for: Battle-injured (BI)

Total 1940 results

RWTH Aachen University

Unknown

Evaluation of the High-resolution, Contrast Enhanced Low-dose Breast-CT

BI-RADS 4 | BI-RADS 5 | BI-RADS 6 | High Risk of Breast Cancer Which Indicates a Mamma-MRI
SynCardia Systems. LLC

Enrolling by invitation

SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection (C2 PAS)

Bi-ventricular Failure
Beth Israel Medical Center

Completed

A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder

Bi-polar II Disorder

United States
Port Said University

Recruiting

Determining the Prevalence of Primary and Secondary Central Line Associated Blood Stream Infection (CLABSI) at the Tertiary Care Hospital (Microbiology)

Central Line-associated Bloodstream Infection (CLABSI)

Egypt
Genentech, Inc.
BioInvent International AB

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Atherosclerosis

United States, Canada
Meir Medical Center

Unknown

Bi-trimalleolar Fracture and APOS System Treatment (APOS-IL 001)

Bi-trimalleolar Fracture of Ankle

Israel
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
London South Bank University
British Acupuncture Council; Confucius Institute for Traditional Chinese Medicine...

Unknown

Warm Needle Acupuncture vs Needle Acupuncture

Osteoarthritis, Knee

United Kingdom
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Jiangjiang Bi

Recruiting

Effect of Gastrectomy on Gut Microbiome and Cognitive Function

Gastric Cancer | Perioperative Neurocognitive Disorders

China
AbbVie
Boehringer Ingelheim

Completed

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Belgium, Canada, Germany, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom
Rigshospitalet, Denmark

Completed

Optimal Cardiac Resynchronization Therapy Pacing Rate

Heart Failure | Quality of Life | Cardiac Resynchronization Therapy | Bi-ventricular Pacing | Sympathetic Activity

Denmark
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Advanced Liver Cancer

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Renal Cell Carcinoma | Advanced Cancer | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
AbbVie

Completed

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Psoriasis

Germany
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn Disease
AbbVie
Boehringer Ingelheim

Completed

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Psoriasis

Germany
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Jianbin Bi

Not yet recruiting

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer (RASTOM)

Metastatic Hormone-Sensitive Prostate Cancer
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel

Advanced Solid Tumors

China
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Cancer Institute and Hospital, Chinese Academy...

Recruiting

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC (SHARP)

Small-cell Lung Cancer | Brain Metastases | SRS | Stereotactic Radiotherapy | Whole Brain Radiotherpay | Hippocampal-avoidance

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Locally Advanced Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (InTRist)

Local Advanced Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Neuromod Devices Ltd.
University Hospital Regensburg

Completed

Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)

Tinnitus

Germany, Ireland
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Guangzhou General Hospital of Guangzhou Military...

Unknown

Correlation of Narcotrend Index and the Observer's Assessment of Alertness/Sedation (OAA/S) Scale

Anesthesia

China
Changhai Hospital

Unknown

Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure

Breast Neoplasms

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany

Search clinical trials for: Battle-injured (BI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations